Clinical Trial

SKB565 for Injection in Advanced Solid Tumors

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase I/II clinical study to evaluate the safety and efficacy of SKB565 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-12 -> 2029-03 2026-08-01
minor Completion pushed: 2029-05 -> 2029-08 2026-08-01
Trial Details
NCT Number NCT07545265
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 180 participants
Start Date 2026-09
Primary Completion 2029-03 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-31